 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...1213141516171819202122...2324» |
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. (Pubmed Central) - Apr 5, 2019
In other trials, ledipasvir/sofosbuvir (± ribavirin) was associated with high SVR12 rates in various CHC populations, including patients with HCV GT2, 3, 4, 5 or 6 infection, cirrhosis, pre and/or post liver or renal transplantation, inherited blood disorders or failure after prior DAA and/or interferon therapy. Thus, ledipasvir/sofosbuvir (± ribavirin) is a valuable effective and generally well tolerated option for adolescent and adult patients with HCV GT1, 4, 5 or 6 infection, including those with HIV co-infection or cirrhosis, with evidence also supporting its use in patients with chronic HCV GT2 or 3 infection.
- | Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Biomarker, Journal: Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. (Pubmed Central) - Apr 5, 2019
...Subgroup analysis on serum NGAL was conducted in those receiving sofosbuvir/ledipasvir, with complete follow-up until week 12 after the end of treatment (FU-12)...In conclusion, compared to a negligible eGFR decline observed in the entire cohort analyzed, a significant NGAL increase was observed after HCV treatment with DAA in a small subgroup. This could reflect tubular damage during DAA treatment rather than glomerular injury.
- Co-administration of directly antiviral agents for HCV and second line MDR-TB drugs: a multi-centre French case series (HALL C) - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_3506;
In this small group of patients, no significant adverse events or drug interactions were observed. DAAs should be considered in patients with HCV co-infection receiving MDR-TB treatment, to increase its tolerability and avoid treatment interruption.
- paritaprevir/ritonavir (ABT-450/r) / AbbVie
The comparison of hepatitis C treatment outcomes with direct acting antivirals between people who inject drugs (PWID) and non-PWID: results from a national survey in Slovenia () - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_1144;
Our results confirm excellent SVR rates of DAAs in real-life setting with better results achieved in non-PWID compared to PWID. However, excluding those with premature treatment discontinuation for unknown reasons and the lack of FU12, the SVR rates were comparable between the two groups.
- | ledipasvir/sofosbuvir / Generic mfg.
New P1/2 trial: Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy (clinicaltrials.gov) - Apr 3, 2019
P1/2, N=24, Recruiting, Sponsor: Ain Shams University
- | tenofovir / ScinoPharm Taiwan
Clinical, Journal: Ledipasvir and Tenofovir drug interaction in HIV-HCV co-infected patients: Impact on Tenofovir Ctrough and Renal Safety. (Pubmed Central) - Apr 3, 2019
Three patients progressed from CKD stage 1 to stage 2 at PT12. A significant increase in tenofovir exposure through P-gp inhibition by ledipasvir was confirmed without significant impact on glomerular renal function in our population with normal renal function or mild renal impairment.
- | Pifeltro (doravirine) / Merck (MSD), Tivicay (dolutegravir) / GSK, ViiV Healthcare
Clinical, PK/PD data, Journal: Clinical Pharmacokinetics and Drug Interactions of Doravirine. (Pubmed Central) - Mar 30, 2019
No clinically significant interactions were noted between doravirine and an antacid (aluminum-magnesium), pantoprazole, ledipasvir/sofosbuvir, or elbasvir/grazoprevir. Further study is needed to better understand doravirine's efficacy and safety profile when co-administered with other agents known to be CYP inducers or inhibitors.
- | tenofovir / ScinoPharm Taiwan, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). (Pubmed Central) - Mar 29, 2019
Further study is needed to better understand doravirine's efficacy and safety profile when co-administered with other agents known to be CYP inducers or inhibitors. LDV/SOF provided a high SVR rate in PI-experienced subjects coinfected with HCV genotype 1 and HIV-1, including patients with cirrhosis.
- | Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, Daklinza (daclatasvir) / BMS
Clinical, Journal: Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C. (Pubmed Central) - Mar 27, 2019
LDV/SOF provided a high SVR rate in PI-experienced subjects coinfected with HCV genotype 1 and HIV-1, including patients with cirrhosis. DAAs were used successfully in the treatment of hepatitis C after orthotopic liver transplantation and resulted in significant improvement in liver function as measured by MELD score, fibrosis level, and cirrhotic clinical condition, even in patients with very advanced disease.
- | Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) / Orchard Therap, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Journal: Successful treatment with Harvoni in an ADA-SCID infant with HCV infection allowed gene therapy with Strimvelis. (Pubmed Central) - Mar 25, 2019
In case of HCV positivity, patients might be excluded from life-saving treatments. As HCV antibodies could be negative in young infant immunodeficient patients due to their immature/impaired immune system, or positive due to maternal-fetal antibody transmission, the risk is usually also evaluated on the basis of the HCV-RNA.
- | Copegus (ribavirin) / Bausch Health, Cimivir-L (sofosbuvir+ledipasvir) / Gilead
Clinical, Journal: Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. (Pubmed Central) - Mar 25, 2019
As HCV antibodies could be negative in young infant immunodeficient patients due to their immature/impaired immune system, or positive due to maternal-fetal antibody transmission, the risk is usually also evaluated on the basis of the HCV-RNA. Ledipasvir-sofosbuvir was well tolerated and highly effective in children 6 to <12 years old with chronic HCV.
- | ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naive patients: findings from two randomized trials. (Pubmed Central) - Mar 21, 2019
Ledipasvir-sofosbuvir was well tolerated and highly effective in children 6 to <12 years old with chronic HCV. In this SOF-experienced NS5A inhibitor-naïve population, which included participants with cirrhosis or HCV/HIV co-infection, high SVR12 rates were achieved.
- || ledipasvir/sofosbuvir / Generic mfg.
Trial completion date, Trial primary completion date, Adherence: Evaluation of HepCure Toolkit to Improve Harvoni Adherence (clinicaltrials.gov) - Mar 11, 2019
P=N/A, N=99, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
In this SOF-experienced NS5A inhibitor-naïve population, which included participants with cirrhosis or HCV/HIV co-infection, high SVR12 rates were achieved. Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
- | NN1213 / Novo Nordisk, Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma, Exviera (dasabuvir) / AbbVie
Trial completion date, Trial primary completion date: DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (clinicaltrials.gov) - Mar 5, 2019
P2/3, N=32, Recruiting, Sponsor: Humanity and Health Research Centre
Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Oct 2020
- | Trial completion date, Trial primary completion date: SWITCH-1: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Feb 28, 2019
P2, N=160, Recruiting, Sponsor: Humanity and Health Research Centre
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Oct 2020 Trial completion date: Mar 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Oct 2020
- ||| ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (clinicaltrials.gov) - Feb 26, 2019
P2, N=95, Completed, Sponsor: Gilead Sciences
Trial completion date: Mar 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Oct 2020 Active, not recruiting --> Completed
- || ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Egypt Peds: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy (clinicaltrials.gov) - Feb 12, 2019
P2, N=19, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
New P4 trial: CHROME: Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication (clinicaltrials.gov) - Jan 31, 2019
P4, N=90, Recruiting, Sponsor: University of Maryland
- || Trial primary completion date: PRIORITIZE: Study of Oral Treatments for Hepatitis C (clinicaltrials.gov) - Jan 29, 2019
P4, N=1676, Active, not recruiting, Sponsor: University of Florida
Active, not recruiting --> Completed Trial primary completion date: Jan 2019 --> Apr 2019
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion date: Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir (clinicaltrials.gov) - Jan 14, 2019
P=N/A, N=15, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jan 2019 --> Apr 2019 Trial completion date: Dec 2018 --> Jun 2019
- ledipasvir/sofosbuvir / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Hepatitis C Virus(HCV) Heart and Lung Study (clinicaltrials.gov) - Dec 21, 2018
P4, N=50, Recruiting, Sponsor: Duke University
Trial completion date: Dec 2018 --> Jun 2019 Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
- | NN1213 / Novo Nordisk
Enrollment closed: STOP-CO: Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant (clinicaltrials.gov) - Dec 20, 2018
P4, N=50, Active, not recruiting, Sponsor: University of California, San Francisco
Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Apr 2019 Recruiting --> Active, not recruiting
- ||||| ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection (clinicaltrials.gov) - Dec 11, 2018
P3b, N=111, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Study of Hepatitis C Treatment During Pregnancy (clinicaltrials.gov) - Dec 6, 2018
P1, N=15, Active, not recruiting, Sponsor: Catherine Chappell
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Feb 2020 | Trial primary completion date: Sep 2019 --> Feb 2020
- | sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion date, Trial primary completion date: BArT: Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection (clinicaltrials.gov) - Nov 20, 2018
P2, N=44, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Feb 2020 | Trial primary completion date: Sep 2019 --> Feb 2020 Trial completion date: Oct 2020 --> May 2022 | Trial primary completion date: Oct 2018 --> May 2019
- | ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Phase classification: Efficacy and Safety of Sofosbuvir/Ledipasvir (clinicaltrials.gov) - Nov 16, 2018
P3b, N=341, Completed, Sponsor: Gilead Sciences
Trial completion date: Oct 2020 --> May 2022 | Trial primary completion date: Oct 2018 --> May 2019 Phase classification: P3 --> P3b
- | ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Treatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/Sofosbuvir (clinicaltrials.gov) - Nov 16, 2018
P4, N=25, Recruiting, Sponsor: Yassin Abdelghaffar Charity Center for Liver Disease and Research
- | ledipasvir/sofosbuvir / Generic mfg.
New P4 trial, Combination therapy: Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease. (clinicaltrials.gov) - Oct 25, 2018
P4, N=10, Recruiting, Sponsor: Mansoura University Children Hospital
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, HEOR: Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection (clinicaltrials.gov) - Oct 25, 2018
P3, N=14, Completed, Sponsor: University Health Network, Toronto
Phase classification: P3 --> P3b Enrolling by invitation --> Completed | N=30 --> 14 | Trial completion date: Feb 2019 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics (clinicaltrials.gov) - Oct 19, 2018
P4, N=30, Active, not recruiting, Sponsor: University of Nebraska
Enrolling by invitation --> Completed | N=30 --> 14 | Trial completion date: Feb 2019 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018 Recruiting --> Active, not recruiting
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial (clinicaltrials.gov) - Oct 11, 2018
P4, N=7, Completed, Sponsor: Ala'a Sharara
Recruiting --> Active, not recruiting Recruiting --> Completed | N=10 --> 7 | Trial completion date: Sep 2017 --> Aug 2018 | Trial primary completion date: Aug 2017 --> Aug 2018
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: STOP-CO: Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant (clinicaltrials.gov) - Sep 24, 2018
P4, N=50, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed | N=10 --> 7 | Trial completion date: Sep 2017 --> Aug 2018 | Trial primary completion date: Aug 2017 --> Aug 2018 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion date, Trial primary completion date: APOSTLE: Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection (clinicaltrials.gov) - Sep 10, 2018
P2, N=10, Recruiting, Sponsor: University of Maryland
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Aug 2018 --> May 2019
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection (clinicaltrials.gov) - Sep 5, 2018
P2, N=226, Completed, Sponsor: Gilead Sciences
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Aug 2018 --> May 2019 Active, not recruiting --> Completed
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. (clinicaltrials.gov) - Aug 31, 2018
P4, N=0, Withdrawn, Sponsor: Kaiser Permanente
Active, not recruiting --> Completed N=20 --> 0 | Trial completion date: Aug 2021 --> Apr 2018 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2018 --> Feb 2018
- | ledipasvir/sofosbuvir / Generic mfg.
New trial: IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir (clinicaltrials.gov) - Aug 22, 2018
P=N/A, N=600, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia (clinicaltrials.gov) - Aug 14, 2018
P4, N=600, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
N=20 --> 0 | Trial completion date: Aug 2021 --> Apr 2018 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Jul 2018
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Enrollment change: Egypt Peds: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy (clinicaltrials.gov) - Aug 6, 2018
P2, N=19, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Jul 2018 Recruiting --> Active, not recruiting | N=40 --> 19
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion: LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients (clinicaltrials.gov) - Jul 13, 2018
P4, N=34, Completed, Sponsor: Medical University of South Carolina
Recruiting --> Active, not recruiting | N=40 --> 19 Active, not recruiting --> Completed
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Trial primary completion date: SHARED: Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World (clinicaltrials.gov) - Jun 28, 2018
P4, N=300, Completed, Sponsor: Partners in Health
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2018
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Trial completion date, Trial primary completion date: A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection (clinicaltrials.gov) - Jun 12, 2018
P=N/A, N=1637, Enrolling by invitation, Sponsor: Gilead Sciences
Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2018 Trial completion date: Nov 2024 --> Aug 2023 | Trial primary completion date: May 2024 --> Aug 2023
- | Trial completion, Enrollment change: Impact of Antiviral Therapy on Gastroesophageal Varices. (clinicaltrials.gov) - May 30, 2018
P=N/A, N=237, Completed, Sponsor: Parc de Salut Mar
Trial completion date: Nov 2024 --> Aug 2023 | Trial primary completion date: May 2024 --> Aug 2023 Active, not recruiting --> Completed | N=374 --> 237
- sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia (clinicaltrials.gov) - Apr 10, 2018
P2/3, N=10, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed | N=374 --> 237 Trial completion date: Feb 2018 --> Dec 2018 | Trial primary completion date: Feb 2018 --> Dec 2018
- ||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (clinicaltrials.gov) - Apr 6, 2018
P2, N=95, Active, not recruiting, Sponsor: Gilead Sciences
Trial completion date: Feb 2018 --> Dec 2018 | Trial primary completion date: Feb 2018 --> Dec 2018 Recruiting --> Active, not recruiting
- | ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Ledipasvir/sofosbuvir is effective and well tolerated in post-kidney transplant patients with chronic hepatitis C virus. (Pubmed Central) - Mar 28, 2018
Serum creatinine remained stable at baseline, end of therapy and last follow up, (1.351 ± .50 mg/dl; 1.406 ± .63 mg/dl; 1.290 ± .39 mg/dl respectively). In post kidney transplant patients with HCV infection with or without co-infection with HIV, a combination of LDV/SOF was well tolerated and effective.
- ||| Zepatier (grazoprevir/elbasvir) / Merck (MSD), Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma, Exviera (dasabuvir) / AbbVie
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: PRIORITIZE: Study of Oral Treatments for Hepatitis C (clinicaltrials.gov) - Mar 22, 2018
P4, N=1670, Active, not recruiting, Sponsor: University of Florida
In post kidney transplant patients with HCV infection with or without co-infection with HIV, a combination of LDV/SOF was well tolerated and effective. Recruiting --> Active, not recruiting | N=2670 --> 1670 | Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Aug 2020 --> Jan 2019
- | Daklinza (daclatasvir) / BMS
Trial completion, Trial completion date: Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients (clinicaltrials.gov) - Mar 19, 2018
P4, N=112, Completed, Sponsor: Humanity and Health Research Centre
Recruiting --> Active, not recruiting | N=2670 --> 1670 | Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Aug 2020 --> Jan 2019 Recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018
- | Pegasys (pegylated interferon ? -2a) / Roche, Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir
Trial completion date, Trial primary completion date: SWITCH-1: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Mar 19, 2018
P2, N=160, Recruiting, Sponsor: Humanity and Health Research Centre
Recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 Trial completion date: Dec 2017 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma, Exviera (dasabuvir) / AbbVie
Trial completion date, Trial primary completion date: DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (clinicaltrials.gov) - Mar 19, 2018
P2/3, N=32, Recruiting, Sponsor: Humanity and Health Research Centre
Trial completion date: Dec 2017 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | daclatasvir/sofosbuvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients (clinicaltrials.gov) - Mar 19, 2018
P3, N=48, Completed, Sponsor: Humanity and Health Research Centre
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 | Trial primary completion date: Sep 2017 --> Dec 2017